In Vivo Immunogenicity Evaluation Service for Veterinary (Pet) Antibody

Are you currently facing challenges in predicting the immune response to your therapeutic antibody in companion animals, concerned about potential loss of efficacy, or navigating the complex preclinical data package required for regulatory approval? Creative Biolabs' in vivo immunogenicity evaluation service helps you precisely characterize the immunogenic potential of your veterinary biologics through our industry-leading assay platforms and species-specific study designs, providing clear, actionable data to accelerate your development pipeline.

Introduction

Evaluating the potential for a therapeutic antibody to elicit an unwanted immune response is a cornerstone of preclinical development. Creative Biolabs provides a comprehensive service designed to deliver a complete immunogenicity profile of your candidate biologic in relevant veterinary species. Our deliverables are critical insights that inform decisions, support regulatory filings, and ultimately, de-risk your entire project. You will receive a full characterization of the antibody response, including incidence, titer levels, and an assessment of their neutralizing potential, all correlated with pharmacokinetic (PK) data and in-life clinical observations for a holistic view of your drug's performance.

Discover How We Can Help - Request a Consultation

Workflow

Ensuring the safety of novel veterinary therapeutic antibodies requires rigorous in vivo toxicological assessment before clinical application. Our service provides a comprehensive framework to evaluate potential toxicities, determine safe dose ranges, and comply with regulatory requirements for companion animal therapeutics.

Antibody In Vivo Immunogenicity Evaluation Service Workflow. (Creative Biolabs Original)Fig 1. Pet Antibody In Vivo Immunogenicity Evaluation Service Workflow. (Creative Biolabs Original)

Study Design & Protocol Development We begin with an in-depth discussion to define your study objectives, target species, and regulatory needs. Our team designs a customized immunogenicity evaluation plan aligned with your antibody's therapeutic indication.
Animal Model Development Appropriate companion animal models are selected based on their relevance to the target patient population. All studies comply with ethical guidelines and animal welfare standards.
Dosing & Administration Your candidate antibody is administered via clinically relevant routes, with dosing schedules optimized to mimic intended therapeutic regimens.
Sample Collection & Monitoring Animals are monitored for clinical signs of immune response. Blood and other relevant biological samples are collected at predefined intervals to capture immune kinetics.
Anti-Drug Antibody (ADA) Detection & Characterization We use sensitive, validated assays to detect and quantify ADAs, followed by classification into neutralizing or non-neutralizing antibodies to assess potential clinical impact.
Data Analysis & Reporting Our scientists deliver a detailed report summarizing immune response magnitude, onset, and duration, along with data-driven recommendations to optimize candidate safety and efficacy before advancing to later-stage studies.

Why Choose Us?

  • Veterinary-First Expertise
    Our deep understanding of canine and feline immunology, physiology, and disease states ensures your study is designed and interpreted within the correct biological context, generating more relevant and translatable data.
  • Fully Integrated Preclinical Services
    Immunogenicity is not an isolated data point. We seamlessly integrate immunogenicity assessments with concurrent in vivo toxicology and PK studies. This holistic approach provides a complete safety and activity profile from a single study, saving you time, resources, and valuable test articles.
  • Robust, Validated Platforms
    We utilize cutting-edge bioanalytical technologies to develop assays with superior sensitivity and drug tolerance. Our methods are rigorously validated according to industry best practices, ensuring the data you receive is reliable, reproducible, and ready for regulatory scrutiny.

CD8⁺ T-cell response in splenocytes. (Rendon-Marin, et al., 2024) (OA Literature)Fig 2. CD8⁺ T-cell immune response in mouse splenocytes by flow cytometry.1,2

FAQs

1. Can you also assess if the detected antibodies are neutralizing (NAbs)?
Absolutely. Assessing neutralizing capacity is a critical part of our tiered approach and is strongly recommended by regulatory agencies. We develop custom cell-based or competitive ligand-binding assays to determine if the detected ADAs are functionally impacting your drug's mechanism of action.
2. How will this immunogenicity data impact my overall drug development program?
The data is pivotal. It directly informs lead candidate selection by helping you choose the least immunogenic molecule. It aids in dose justification and risk assessment for regulatory filings. Ultimately, a clean immunogenicity profile significantly increases the probability of success in clinical trials and leads to a safer, more effective therapeutic for pets.

Related Services

To provide a complete preclinical data package, we recommend complementing your immunogenicity studies with our other expert services.

(Creative Biolabs Authorized)In Vivo Toxicological Evaluation

Our toxicology studies provide comprehensive safety data required to support your regulatory submissions.

(Creative Biolabs Authorized)Animal Model Customization

We develop and characterize specific disease models in companion animals to test the efficacy of your novel therapeutics in a clinically relevant setting.

Partner with Creative Biolabs

Creative Biolabs is your dedicated partner for preclinical veterinary research. Our specialized in vivo immunogenicity evaluation service provides the clear, reliable, and actionable data you need to confidently advance your therapeutic antibody from the laboratory to the clinic. We are committed to helping you develop safer and more effective treatments for companion animals.

Ready to ensure the safety and efficacy of your veterinary therapeutic? Let our experts guide you through the process. Contact our team to learn more about our customized solutions for your pet therapeutic antibody in vivo immunogenicity evaluation project.

Contact Our Team for More Information and to Discuss Your Project.

References

  1. Rendon-Marin, Santiago et al. "Evaluation of the Safety and Immunogenicity of a Multiple Epitope Polypeptide from Canine Distemper Virus (CDV) in Mice." Vaccines vol. 12,10 1140. 4 Oct. 2024, https://doi.org/10.3390/vaccines12101140
  2. Distributed under Open Access license CC BY 4.0, without modification.
Services

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.